Mesoblast Limited Sponsored ADR Stock

$10.86

10.40% yesterday

Nasdaq, Jul 02, 10:00 pm CET

ISIN

US5907171046

Symbol

MESO

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Mesoblast Limited Sponsored ADR Stock price

$10.86

-13.22 54.90% 5Y

Nasdaq, Closing price Wed, Jul 02 2025

-1.26 10.40%

ISIN

US5907171046

Symbol

MESO

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$1.4b

Enterprise Value

$1.5b

Net debt

$88.5m

Cash

$37.7m

Shares outstanding

1.2b

Valuation (TTM | estimate)

P/E

negative | negative

P/S

245.24 | 84.72

EV/Sales

260.84 | 90.11

EV/FCF

negative

P/B

30.28

Financial Health

Equity Ratio

71.79%

Return on Equity

-18.31%

ROCE

-13.81%

ROIC

-14.19%

Debt/Equity

0.27

Financials (TTM | estimate)

Revenue

$5.7m | $16.4m

EBITDA

- | $-61.0m

EBIT

$-80.2m

Net Income

$-103.4m | $-464.4m

Free Cash Flow

$-42.7m

Growth (TTM | estimate)

Revenue

-24.10% | 178.19%

EBITDA

- | 6.76%

EBIT

-44.91%

Net Income

-41.46% | -427.99%

Free Cash Flow

28.04%

Margin (TTM | estimate)

Gross

201.75%

EBITDA

- | -371.69%

EBIT

-1,414.43%

Net

-1,822.77% | -2,829.60%

Free Cash Flow

-753.51%

EPS

$-0.09

FCF per Share

$-0.04

Short interest

2.67%

Employees

73.00

Rev per Employee

$80.00k

As a Free StocksGuide user, you can view scores for all 6,965 stocks worldwide.

Get Started for Free Today

Mesoblast Limited Sponsored ADR Stock Analysis

Unlock Scores for Free

??

9 Analysts have issued a Mesoblast Limited Sponsored ADR forecast:

7x Buy

78%

2x Hold

22%

More details on Analyst Estimates Including Price Targets

9 Analysts have issued a Mesoblast Limited Sponsored ADR forecast:

Buy

78%

Hold

22%

Analyst Estimates with Stock Price Targets

Financial data from Mesoblast Limited Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	5.67 5.67	24% 24% 100%
- Direct Costs	-5.77 -5.77	127% 127% -102%
Gross Profit	11 11	180% 180% 202%
- Selling and Administrative Expenses	29 29	24% 24% 517%
- Research and Development Expense	33 33	30% 30% 588%
EBITDA	- -	- -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-80 -80	45% 45% -1,414%
Net Profit	-103 -103	41% 41% -1,823%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Mesoblast Limited Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

2 days ago

Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items required for filing a Biologics License Application (BLA) for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic heart failure with...

Neutral

GlobeNewsWire

●

21 days ago

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure wi...

Neutral

GlobeNewsWire

●

about 2 months ago

FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®

NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received seven years of orphan-drug exclusive approval from U.S. Food and Drug Administration (FDA) for Ryoncil® (remestemcel-L) for treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatr...

More Mesoblast Limited Sponsored ADR News

Company Profile

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.

Head office	Australia
CEO	Silviu Itescu
Employees	73
Founded	2004
Website	www.mesoblast.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now